Amarin Co. plc (NASDAQ:AMRN) shares reached a new 52-week high during trading on Monday after SunTrust Banks raised their price target on the stock to $30.00. SunTrust Banks currently has a reduce rating on the stock. Amarin traded as high as $23.14 and last traded at $22.99, with a volume of 325840 shares traded. The stock had previously closed at $22.87.
Several other research analysts have also commented on AMRN. Cantor Fitzgerald set a $10.00 price target on Amarin and gave the stock a “buy” rating in a research report on Wednesday, July 18th. Zacks Investment Research lowered Amarin from a “hold” rating to a “sell” rating in a research report on Tuesday, July 24th. ValuEngine lowered Amarin from a “buy” rating to a “hold” rating in a report on Saturday, July 28th. Finally, BidaskClub raised Amarin from a “sell” rating to a “hold” rating in a report on Wednesday, August 29th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $27.80.
In other news, General Counsel Joseph T. Kennedy sold 23,307 shares of the business’s stock in a transaction that occurred on Wednesday, October 31st. The stock was sold at an average price of $20.74, for a total value of $483,387.18. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Steven B. Ketchum sold 879,241 shares of the business’s stock in a transaction that occurred on Tuesday, September 25th. The shares were sold at an average price of $11.10, for a total value of $9,759,575.10. The disclosure for this sale can be found here. In the last three months, insiders sold 3,016,149 shares of company stock worth $34,812,617. Corporate insiders own 4.08% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. Signature Estate & Investment Advisors LLC acquired a new position in shares of Amarin in the third quarter valued at approximately $137,000. BKS Advisors LLC acquired a new position in shares of Amarin in the third quarter valued at approximately $162,000. Private Advisor Group LLC increased its holdings in shares of Amarin by 17.8% in the third quarter. Private Advisor Group LLC now owns 79,735 shares of the biopharmaceutical company’s stock valued at $1,297,000 after purchasing an additional 12,049 shares during the period. Cambridge Investment Research Advisors Inc. increased its holdings in shares of Amarin by 165.5% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 31,125 shares of the biopharmaceutical company’s stock valued at $506,000 after purchasing an additional 19,400 shares during the period. Finally, Northern Trust Corp increased its holdings in shares of Amarin by 20.9% in the second quarter. Northern Trust Corp now owns 113,327 shares of the biopharmaceutical company’s stock valued at $350,000 after purchasing an additional 19,590 shares during the period. 39.44% of the stock is currently owned by institutional investors and hedge funds.
The firm has a market capitalization of $6.69 billion, a price-to-earnings ratio of -91.92 and a beta of 0.70.
Amarin (NASDAQ:AMRN) last announced its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.01. The business had revenue of $55.00 million for the quarter, compared to analyst estimates of $60.63 million. During the same period in the prior year, the company earned ($0.04) EPS. The company’s revenue was up 16.8% on a year-over-year basis. Sell-side analysts expect that Amarin Co. plc will post -0.42 EPS for the current year.
WARNING: “Amarin (AMRN) Reaches New 12-Month High Following Analyst Upgrade” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/11/06/amarin-amrn-reaches-new-12-month-high-following-analyst-upgrade.html.
Amarin Company Profile (NASDAQ:AMRN)
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Recommended Story: Day Trading – Risk Worth the Reward?
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.